NantKwest

89 articles about NantKwest

• NantKwest Appoints Dr. John Lee As Senior Vice President Of Adult Medical Affairs

  5/18/2017

• NantKwest Appoints Dr. Leonard Sender As Senior Vice President Of Medical Affairs For Pediatric, Adolescent And Young Adult Oncology

  5/16/2017

• NantKwest And NantCell Announce FDA Authorization For The NANT Cancer Vaccine Clinical Trials, The First Novel Combination Of Innate And Adaptive Immunotherapy In Patients With Pancreatic Cancer

  5/9/2017

• World's Richest Doctor Allegedly Threatened to Abandon Investment Unless Troubled Media Firm Invested in NantKwest

  4/4/2017

• NantKwest And Viracta Therapeutics Announce Series B Financing And Immunotherapy Partnership

  4/4/2017

• NantKwest Announces FDA Grant Of Orphan Drug Designation For The Company’s aNK Natural Killer Cell Therapy In Merkel Cell Carcinoma

  3/20/2017

• NantKwest Release: Landmark First-In-Human Clinical Study Launch Using A Genetically Engineered Natural Killer Cell For The Treatment Of Cancer

  1/23/2017

• NantKwest CEO (AKA World's Richest Doctor) Rumored to Have Met Trump for Top NIH Job

  1/17/2017

• NantKwest Announces Enhanced High-Affinity Activated Natural Killer (Hank) Cell Therapy In Preclinical Studies Of HER2 Positive Breast Cancer At Presentation At The San Antonio Breast Cancer Symposium

  12/12/2016

• NantHealth, NantKwest And Nantomics Announce Availability Of GPS Cancer And Phase I – III QUILT Trials Through The U.S. NantKwest’s Clinicaltrials.Gov

  12/8/2016

• NantKwest Release: Direct Injection Of CAR-Engineered CD19.taNK Cells Demonstrating Potential "Vaccine" Protective Effect To Be Highlighted In Oral Presentation At The 58th Annual Meeting Of American Society of Hematology

  11/23/2016

• NantKwest Announces Landmark Study Published On high affinity haNK Cell Therapy In The Journal Oncotarget

  11/23/2016

• NantKwest Announces Achievement Of End Point In Merkel Cell Carcinoma Phase II Trial With Evidence Of Efficacy Of Activated Natural Killer (Ank) Cells In Solid Tumors

  11/15/2016

• Altor BioScience Corporation And NantKwest Announce Co-Development Agreement To Advance Innovative Natural Killer Cell Combination Immunotherapies For The Treatment Of Cancer

  10/4/2016

• NantKwest Announces Presentations At Upcoming Investment Conferences

  9/12/2016

• NantKwest CEO's $329.7 Million Pay Package Might Make Him the Highest-Paid U.S. Executive

  4/29/2016

• NantKwest To Present Data On The First Next Generation GMP-Grade NK Cell Line For Combination Immunotherapy With Rituximab, Trastuzumab, And Daratumumab At Upcoming AACR Cancer Conference

  4/18/2016

• NantBioscience Partner With The NantKwest To Further Develop Recombinant NK Cells And Monoclonal Antibodies As Monotherapies And Combination Cancer Immunotherapies

  4/5/2016

• NantKwest Names Fatih M. Uckun, M.D., Vice President Of Research And Clinical Development

  3/14/2016

• NantKwest Added To Nasdaq Biotechnology Index

  12/18/2015